Moving Towards AI, ML, And Trial Platforms For True Scalability

As the life sciences industry continues to advance, there are still 10,000 human diseases that need to be addressed so that treatments can be developed for those infected. Nearly two years ago, Medable CEO Michelle Longmire inquired what that path might look like in a blog titled "Accelerating the journey from possibility to evidence in the development of new medicines." At that time, she emphasized the importance of harnessing the most impactful tools available to drive synergies at the intersection of safety, science, and speed, thus ushering in a new era of drug development.

Today, the industry finds itself on the brink of a fresh chapter in clinical research characterized by rapid advancements in technologies commonly referred to as artificial intelligence and machine learning (AI and ML). While both these technologies have been around for a while, recent enhancements in their capabilities have propelled them to the forefront of our industry.

Uncover in this article, how in the coming years, AI and ML could have the potential to emerge as pivotal technologies of our era, offering the prospect of true scalability in the pharmaceutical sector and across various other industries.